Andre J Scheen
Overview
Explore the profile of Andre J Scheen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
231
Citations
4019
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Scheen A
Diabetes Metab
. 2023 Sep;
49(5):101474.
PMID: 37678760
Stroke represents a major burden in patients with type 2 diabetes, yet this cerebrovascular complication has been less carefully investigated than the risk of cardiovascular mortality, heart failure and renal...
12.
Scheen A
Expert Opin Drug Metab Toxicol
. 2023 Aug;
19(8):543-553.
PMID: 37620287
Introduction: Type 2 diabetes and liver disease, mainly metabolic-associated fatty liver disease (MAFLD) and more rarely cirrhosis, coexist in many patients. This duality has direct implications for the physician when...
13.
Scheen A
Rev Med Suisse
. 2023 Aug;
19(838):1498-1502.
PMID: 37610193
Metabolic-Associated Fatty Liver Disease (MAFLD) is a prevalent metabolic complication among patients with obesity and type 2 diabetes, associated with bad prognosis. Classical antidiabetics have little effects on this complication,...
14.
Scheen A
Rev Med Suisse
. 2023 Aug;
19(838):1492-1495.
PMID: 37610192
The management of type 2 diabetes (T2D) after a gastric bypass or a sleeve gastrectomy requires some cautions depending on the timing after the surgical procedure and the patient evolution....
15.
16.
Scheen A
Lancet Diabetes Endocrinol
. 2023 Jul;
11(9):626-627.
PMID: 37499674
No abstract available.
17.
Scheen A
Diabetes Metab
. 2023 May;
49(4):101453.
PMID: 37245675
Bariatric/metabolic surgery and sodium-glucose cotransporter 2 inhibitors (SGLT2is) are becoming increasingly popular for the management of overweight/obese patients with type 2 diabetes mellitus (T2DM). Consequently, the chance that a patient...
18.
Scheen A
Expert Rev Endocrinol Metab
. 2023 May;
18(4):271-282.
PMID: 37154218
Introduction: Sodium-glucose cotransporter 2 inhibitors (SGLT2is, gliflozins), the most recent oral antihyperglycaemic agents, provide a cardiorenal protection, an effect independent of their glucose-lowering potency. Areas Covered: The antihyperglycaemic potency of...
19.
20.
Scheen A
Ann Endocrinol (Paris)
. 2023 Mar;
84(3):357-363.
PMID: 36963753
Psychotropic drugs may be associated with metabolic disorders, often but not only triggered by weight gain. Disorders include dysglycemia and diabetes, atherogenic dyslipidemia and metabolic syndrome. Overall, metabolic risk is...